UroGen Secures U.S. Patent for Bladder Cancer Treatment Through 2044
Event summary
- UroGen received a Notice of Allowance from the USPTO for a patent covering methods of treating recurrent, low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) without surgery.
- The patent, expected to expire in July 2044, is based on data from the ENVISION and ATLAS clinical trials and supports ZUSDURI™ and UGN-103.
- UGN-103, developed with medac, extends intellectual property protection into December 2041 and includes next-generation enhancements like streamlined manufacturing.
The big picture
UroGen’s new patent strengthens its position in the non-surgical treatment of bladder cancer, a segment with significant unmet needs. The company’s RTGel technology, which enables sustained drug delivery, aligns with broader industry trends toward targeted, less invasive therapies. The partnership with medac further bolsters UroGen’s ability to innovate and commercialize next-generation treatments.
What we're watching
- Patent Protection
- The duration of patent protection for ZUSDURI and UGN-103 will determine UroGen's competitive advantage in the non-surgical bladder cancer treatment market.
- Clinical Trial Data
- The success of future clinical trials, particularly for UGN-103, will be critical in reinforcing the company’s proprietary RTGel technology and expanding its commercial portfolio.
- Market Adoption
- The pace at which ZUSDURI and UGN-103 gain market acceptance will impact UroGen's long-term growth opportunities in treating urothelial cancers.
Related topics